915226-65-2

Basic information

• Product Name: (S)-1-(4-fluoro-benzoyl)-N-hydroxy-piperidine-3-carboxamidine
• Synonyms: (S)-1-(4-fluoro-benzoyl)-N-hydroxy-piperidine-3-carboxamidine
• CAS NO: 915226-65-2
• Molecular Weight: 265.287
• Mol File: 915226-65-2.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: (S)-1-(4-fluoro-benzoyl)-N-hydroxy-piperidine-3-carboxamidine(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-1-(4-fluoro-benzoyl)-N-hydroxy-piperidine-3-carboxamidine(915226-65-2)
• EPA Substance Registry System: (S)-1-(4-fluoro-benzoyl)-N-hydroxy-piperidine-3-carboxamidine(915226-65-2)

Safety Data

• Hazardous Substances Data: 915226-65-2(Hazardous Substances Data)

Upstream product

• 88495-54-9 (3S)-1-(tert-butoxycarbonyl)piperidine-3-carboxylic acid 
• 403-43-0 4-fluorobenzoyl chloride 
• 915226-72-1 (S)-piperidine-3-carbonitrile hydrochloride 
• 915226-39-0 (S)-3-carbamoyl-piperidine-1-carboxylic acid tert-butyl ester 
• 915226-64-1 (S)-1-(4-fluoro-benzoyl)-piperidine-3-carbonitrile 
• 88466-77-7 (S)-3-carbamoyl-piperidine-1-carboxylic acid tert-butyl ester 

Downstream Products

• 915226-31-2 (4-fluoro-phenyl)-{(S)-3-[5-(1-methyl-1H-imidazol-4-yl)-[1,2,4]oxadiazol-3-yl]-piperidin-1-yl}-methanone 
• 915226-27-6 (S)-(4-fluorophenyl)-{3-[5-(5-fluoropyridin-2-yl)-[1,2,4]oxadiazol-3-yl]-piperidin-1-yl}-methanone 

Relevant articles and documents

Substituted Oxadiazole Derivatives as Positive Allosteric Modulators of Metabotropic Glutamate Receptors

The present invention relates to new compounds which are Oxadiazole derivatives of formula (I) wherein B, P, Q, W, R1 and R2 are defined in the description. Invention compounds are useful in the prevention or treatment of central or peripheral nervous system disorders as well as other disorders modulated by mGluR5 receptors.(I).

NOVEL HETEROCYCLIC COMPOUNDS AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS

The present invention relates to new compounds which are Heterocyclic derivatives of formula (I) wherein A, B, P, X, Y, Q, W, R1 and R2 are defined in the description. Invention compounds are useful for treating central or peripheral nervous system disorders and other disorders which are affected by the neuromodulatory effect of mGluR5 positive allosteric modulators such as cognitive decline and also to treat both positive and negative symptoms in schizophrenia.